Engineered T-Cells take aim at Hard-to-Treat pancreatic cancer

NCT ID NCT04809766

Terminated Disease control Sponsor: Fred Hutchinson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This early-phase trial tests a personalized cell therapy for people with metastatic pancreatic cancer. A patient's own T-cells are genetically modified to recognize and attack mesothelin, a protein found on many pancreatic cancer cells. Before receiving the modified cells, patients get chemotherapy to help the T-cells work better. The study aims to find a safe dose and understand side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Mesothelin-specific TCR-T cells (FH-TCR-Tᵐˢˡⁿ)
What this could lead to: If successful, this approach could offer a new treatment option for people with metastatic pancreatic cancer, a disease with very few effective therapies.
What could go wrong: This is an early phase 1 trial with only 9 participants, so safety and dosing are still being evaluated. The therapy may cause serious side effects, and it is too soon to know if it will shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA STAGE IV PANCREATIC CANCER AJCC V8

Contacts and locations

Locations

Fred Hutch/University of Washington Cancer Consortium

Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.